Table 2. . Avapritinib characteristics including response rates, progression free time, outcomes and toxicities.

	Dose	Response	Progression-free time	Outcomes	Toxicities
A	300 mg	Initial SD at 3 months followed by PD at 6 months	6 months	On ripretinib	Grade 3 rash, greying of hair, grade 2 hyperbilirubinemia, grade 2 anemia
B	300 mg	Initial PR at 2 months, SD at 5 months followed by PD at 8 months	8 months	Planned for ripretinib	Grade 2 rash, periorbital puffiness, grade 4 SDH
C	300 mg	PD	5 months	Planned for ripretinib	Grade 2 rash
D	300 mg	Not available	1 months	Death	Grade 2 hyperbilirubinemia
E	300 mg	PR	3 months	On avapritinib	Periorbital puffiness, pleural effusion

PD: Progressive disease; PR: Partial response; SD: Stable disease; SDH: Subdural hemorrhage.